Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05629091
Other study ID # Fibdex 1-2022
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 12, 2023
Est. completion date August 30, 2024

Study information

Verified date October 2023
Source UPM Biomedicals
Contact Johana Kuncova-Kallio
Phone +35820415111
Email johana.kuncova-kallio@upm.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, randomised, open-label, within-patient controlled, non-inferiority clinical investigation of the nanofibrillar cellulose (NFC) wound dressing FibDex® for treatment of superficial dermal burns in paediatric and adult patients. The clinical performance and safety of FibDex® will be compared to Epicitehydro (QRSKIN GmbH, Würzburg, Germany) and Epiprotect® (S2Medical AB, Linköping, Sweden). Epicitehydro is considered to be the primary comparator. The investigation will be conducted at 2 clinical research sites in Sweden.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date August 30, 2024
Est. primary completion date August 30, 2024
Accepts healthy volunteers No
Gender All
Age group 1 Year and older
Eligibility Inclusion Criteria: 1. Signed written informed consent (by the patient and/or the patient's parent[s]/legal guardian[s] as applicable). 2. Patient with superficial dermal burn wound(s) (class II/A) =36h as assessed by the Investigator. 3. Patient at least 1 year old. 4. Patient who has at least 3 superficial dermal burn wounds on anatomically equivalent areas or a superficial dermal burn large enough to allow a lateral comparison. 5. Wound area at least 50 cm2 (per wound, if 3 separate wounds) or at least 150 cm2 (if single wound) as judged by the Investigator. Exclusion Criteria: 1. Patient hyper-sensitive or allergic to, or have had a hypersensitivity/allergic reaction to, any of the dressing components. 2. Pregnant or breast-feeding female. 3. Patient with chemically or electrically induced burns. 4. Other non-burn wound in target wound area. 5. Not suitable for inclusion according to the Investigator. 6. Cognitive dysfunction or psychiatric history (Investigator's discretion). 7. Chronic or presently active skin condition that is judged as interfering with normal wound healing process (Investigator's discretion) 8. Target burns on sensitive skin areas, such as the facial or genital area. 9. Inability or unwillingness of participant or parent(s)/legal guardian(s) to give written informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
FibDex
Nanofibrillar cellulose wound dressing
Epicite hydro
Wound dressing
Epiprotect
Wound dressing

Locations

Country Name City State
Sweden Burn Centre, Uppsala University Hospital Uppsala

Sponsors (2)

Lead Sponsor Collaborator
UPM Biomedicals CTC Clinical Trial Consultants AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Non-inferiority of FibDex® compared to Epicitehydro in terms of time to clinical wound healing (days) defined as no need of any dressing (inner or outer) At each clinical visit, the Investigator or delegate will assess and record in the eCRF if the inner dressing(s) has detached and judge whether or not there is a need for outer dressing. Within 2 to 3 weeks (until the wound has healed)
Secondary Non-inferiority of FibDex® compared to Epiprotect® in terms of time to clinical wound healing (days) defined as no need of any dressing (inner or outer). At each clinical visit, the Investigator or delegate will assess and record in the eCRF if the inner dressing(s) has detached and judge whether or not there is a need for outer dressing. Within 2 to 3 weeks (until the wound has healed)
Secondary Non-inferiority FibDex® compared to Epicitehydro and Epiprotect®, respectively, in terms of re-epithelialisation of the initial wound area over time Percentage of re-epithelialisation will be evaluated by visual observation by the Investigator or delegate and classified according following categories: <50%, 50-75%, 76-90%, 90-95% and 96-100%. Within 2 to 3 weeks (until the wound has healed)
Secondary Evaluate degree of experienced pain On Day 1, pain will be measured before application of FibDex® and the comparators and after outer layer dressing application. On the subsequent visits, pain will be measured before (background pain) and after (procedural pain) outer layer dressing change during the wound healing period. Patients aged =8 years will rate subjective pain using a Numeric Pain Rating Scale (NPRS) 0-10 (0 representing no pain and 10 representing the worst possible pain). Patients aged 4 to 7 years will rate pain using The Faces Pain Scale 0-10 (0 representing no pain and 10 representing very much pain). The Faces, Legs, Activity, Cry, Consolability (FLACC) 0-10 (0 is relaxed and comfortable and 7-10 is severe pain or discomfort or both) behavioural measurement will be used for assessment of pain in patients aged =3 years. Within 2 to 3 weeks (until the wound has healed)
Secondary Assess clinical performance in terms of number of wound infections The burn will be diagnosed with wound infection if at least 2 of the criteria based on the definition of burn wound infection stated by the American Burn Association, are fulfilled. Within 2 to 3 weeks (until the wound has healed)
Secondary Need for surgical intervention If wounds, during subsequent dressing changes and assessments, is judged as not progressing in a favourable direction, or if time from trauma approaches/exceeds 2 to 3 weeks, surgical intervention should be considered. Within 2 to 3 weeks (until the wound has healed)
Secondary Assess clinical performance in terms of length of stay (days) at hospital All patients hospitalised for their burns will be monitored by a research nurse. The day of discharge will be recorded in the eCRF. Any readmission after the initial discharge will also be noted in the eCRF and included in the total length of stay. Within 2 to 3 weeks (until the wound has healed)
Secondary Assess clinical performance in terms of number of outer layer dressing changes Outer dressings will be changed at each visit (from Visit 3 and onwards) if deemed appropriate by the Investigator Within 2 to 3 weeks (until the wound has healed)
Secondary Evaluate scar quality Burn scar outcome will be evaluated using the Patient and Observer Scar Assessment Scale (POSAS). For both the patient and the observer, the score for each item is added (1 - 10 where 10 indicates the worst imaginable sensation or scar and 1 corresponds to normal skin. Moreover, observer scale nominal variables, such as type of pigmentation, may be recorded in category boxes in addition to the 10 point scale. Lastly, the patient and observer score their "Overall Opinion" of the scar compared to normal skin with the same 10 point scale, where 1 is normal skin and 10 is the most markedly different scar. 3, 6 and 12 months post burn
Secondary Monitor Adverse Events (AEs) Frequency, intensity and seriousness of AEs Within 2 to 3 weeks (until the wound has healed)
Secondary Monitor Device Deficiencies (DDs) Frequency and nature of DDs Within 2 to 3 weeks (until the wound has healed)
See also
  Status Clinical Trial Phase
Completed NCT05023135 - DeepView SnapShot Portable (DV-SSP): Device Training Study
Completed NCT05276869 - Reliability and Feasibility of WeeFIM Instrument to Measure Functional Independence in Pediatric Burns
Completed NCT04548635 - VR for Burn Dressing Changes at Home Phase 2/Phase 3
Not yet recruiting NCT06076031 - Effects of Applying Streaming Media on Reducing Pain in Patient With Second-degree Burn During Changing Dressing N/A
Recruiting NCT05084248 - Vitamin D Deficiency in Adults Following a Major Burn Injury Phase 4
Completed NCT03113253 - TRANexamic Acid to Reduce Bleeding in BURN Surgery Phase 4
Recruiting NCT04090424 - Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT03159182 - Study of Silicone Material Inserts To Treat Burn Scars N/A
Recruiting NCT02904941 - Human Amniotic Versus Synthetic Membrane as a Transient Skin Cover for Pediatric Burns N/A
Completed NCT02681757 - Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT01437852 - StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns Phase 1
Completed NCT01214811 - Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing Phase 3
Completed NCT01061502 - Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds Phase 1/Phase 2
Terminated NCT00822796 - Thermogard™ Efficacy Trial N/A
Terminated NCT00824681 - Effect of Music Therapy on Families of Burn Patients Phase 1
Terminated NCT00634166 - Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group Phase 4
Terminated NCT00464386 - Continuous Glucose Monitoring (POC) in the ICU N/A
Withdrawn NCT00216983 - Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding N/A